Prostate Cancer Genomic Classifier VL

Transcriptome-Based Prognostic and Predictive Biomarker Analysis - The DECIPHER Genomic Classifier for Prostate Cancer - Ashley Ross

Details
Alicia Morgans and Ashley Ross discuss how the Decipher prognostic biomarker prostate classifier is being integrated into phase II and III clinical trials, a 22-gene prognostic biomarker that provides a score that indicates the aggressiveness of an individual patient’s cancer, to help healthcare professionals more accurately categorize risk and select appropriate treatment. The pair highlights dat...

The Use of Genomics in Unfavorable Intermediate-risk Prostate Cancer - David Morris

Details
David Morris joins Ashley Ross in a conversation on genomics in prostate cancer specifically, in the unfavorable intermediate-risk patient. Drs Morris and Ross highlight the use of genomics in decision-making when considering what the best treatment option is for this group of individuals. They are particularly interested in determining if any of these intermediate-risk patients might actually be...

PORTOS as a Predictive Biomarker to Help Personalize Radiotherapy Dose in the Postoperative Setting, in the SAKK 09/10 Trial - Alan Dal Pra

Details
Alan Dal Pra joins Alicia Morgans in a discussion on the prognostic and predictive performance of the 24-gene Post-Operative Radiation Therapy Outcome Score, the PORTOS signature in the phase 3 randomized clinical trial assessing dose escalation after radical prostatectomy, the SAKK 09/10 trial. The SAKK 09/10 was a multicenter, randomized phase III trial performed across 24 centers in Switzerland...

Insights from the STAMPEDE Trial Platform - Marina Parry & Gerhardt Attard

Details
Marina Parry and Gerhardt Attard join Alicia Morgans in discussing two key studies from the STAMPEDE trial platform, including “Comparison of abiraterone acetate and prednisolone or combination enzalutamide + abiraterone acetate and prednisolone for metastatic hormone-sensitive prostate cancer (mHSPC) starting ADT: overall survival (OS) results of 2 randomized Phase III trials from the STAMPEDE pr...

The Molecular Biology of Prostate Cancer - Christopher Barbieri

Details
Christopher Barbieri joins Matthew Cooperberg for a discussion about the molecular biology of localized prostate cancer. Dr. Barbieri explains how the underlying molecular and genomic features that separate prostate cancer subtypes can be studied using DNA sequencing and RNA sequencing. The conversation covers predictive markers including DECIPHER, PAM50, genomic mutations, and oncogenic drivers....

An Ancillary Study of the STAMPEDE Trial Assessing the Clinical Qualification of Transcriptome Signatures for Advanced Prostate Cancer Starting ADT +/- Abiraterone Acetate and Prednisolone - Gerhardt...

Details
Gerhardt Attard joins Ashley Ross in discussing an ancillary study of the STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone. The addition of abiraterone acetate and prednisolone to ADT is the standard of care for advanced prostate cancer (metastatic, M1 and high-risk non-met...

Adjuvant Treatment for Men with Prostate Cancer with High Risk of Metastasis, the ERADICATE Study - Ashley Ross

Details
In this discussion, Alicia Morgans and Ashley Ross discuss men in the adjuvant setting with the highest risk of prostate cancer metastasis by genomic stratification. They focus their discussion on Decipher molecular testing after prostatectomy and the Phase III ERADICATE study. The ERADICATE trial was presented at this year's ASCO meeting. Biographies: Ashley Ross, MD, Ph.D., Associate Professor,...

Rationale for the Use of Decipher RP Genomic Classifier to Inform Treatment - Ashley Ross

Details
Alicia Morgans and Ashley Ross discuss Decipher RP genomic classifier for prostatectomy specimens, and how to integrate these tests into clinical practice. Decipher is a genomic classifier that looks at the whole genome and expression patterns on that genome. The genomic classifier score is a prognostic score that goes from 0 to 1, and it was first developed to stratify the risk of metastatic prog...

The Use of the Decipher Biopsy Test Prior to Prostatectomy - Ashley Ross

Details
Alicia Morgans and Ashley Ross discuss the Decipher Biopsy genomic risk assessment test and its use prior to prostatectomy. Dr Ross shares how and why he has integrated this genomic risk stratification test into his clinical practice. The use of Decipher allows patients to be risk stratified based upon the genomics of the tumor tissue and physicians can use the results to determine the course of t...

Decipher Biopsy and Decipher for Prostatectomy in Clinical Practice- Ashley Ross

Details
Alicia Morgans and Ashley Ross discuss Decipher testing, both Decipher Biopsy and Decipher for prostatectomy specimens, and how to integrate these tests into standard clinical practice. Decipher is a genomic classifier that looks at the whole genome and expression patterns on that genome. The genomic classifier score is a prognostic score that goes from 0 to 1, and it was first developed to strati...
email news signup